BDBM253928 US10189849, Compound 27::US10927120, Compound 27::US9464092, T::US9527857, T::US9957276, Compound 27

SMILES CN1CCN(CC1)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1

InChI Key InChIKey=PDGKHKMBHVFCMG-UHFFFAOYSA-N

Data  19 IC50  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 21 hits for monomerid = 253928   

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  0.800nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  5.05E+4nMAssay Description:For the measurement of CDK2/cyclinE activity, enzyme (0.22 nM) was incubated with 100 mM ATP and the phosphoacceptor substrate peptide (1 mM) for one...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-A2/Cyclin-dependent kinase 2(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  1.67E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  0.821nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  1.66nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-A2/Cyclin-dependent kinase 2(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  1.67nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  5.64nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  1.66E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-A1/Cyclin-dependent kinase 2(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  1.67E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  0.800nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  0.821nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  1.66E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  0.800nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-A2/Cyclin-dependent kinase 2(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  1.67E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif.) to determ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  5.05E+4nMAssay Description:Kinase enzymatic reactions were performed in 384-well microplates using a 12-channel Caliper LabChip instrument as a detection device. The enzymatic ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  5.05E+4nMAssay Description:Kinase enzymatic reactions were performed in 384-well microplates using a 12-channel Caliper LabChip instrument as a detection device. The enzymatic ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  4nMAssay Description:Inhibition of human CDK6/cyclin D3More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  1nMAssay Description:Inhibition of human CDK4/cyclinD1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataEC50: <100nMAssay Description:Inhibition of human CDK4/cyclinD1More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataEC50: <100nMAssay Description:Inhibition of human CDK2/cyclin EMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Gi Therapeutics

US Patent
LigandPNGBDBM253928(US10189849, Compound 27 | US10927120, Compound 27 ...)
Affinity DataIC50:  1.66E+3nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
In DepthDetails US Patent